707 related articles for article (PubMed ID: 15494604)
1. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
Han JY; Oh SH; Morgillo F; Myers JN; Kim E; Hong WK; Lee HY
J Natl Cancer Inst; 2005 Sep; 97(17):1272-86. PubMed ID: 16145048
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
Lee HY; Chun KH; Liu B; Wiehle SA; Cristiano RJ; Hong WK; Cohen P; Kurie JM
Cancer Res; 2002 Jun; 62(12):3530-7. PubMed ID: 12068000
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
5. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Smalley KS; Eisen TG
Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
[TBL] [Abstract][Full Text] [Related]
6. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
7. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
Chun KH; Lee HY; Hassan K; Khuri F; Hong WK; Lotan R
Cancer Res; 2003 Aug; 63(16):4796-800. PubMed ID: 12941797
[TBL] [Abstract][Full Text] [Related]
8. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
9. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Sun SY; Zhou Z; Wang R; Fu H; Khuri FR
Cancer Biol Ther; 2004 Nov; 3(11):1092-8; discussion 1099-1101. PubMed ID: 15467440
[TBL] [Abstract][Full Text] [Related]
10. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
[TBL] [Abstract][Full Text] [Related]
11. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Adjei AA; Davis JN; Bruzek LM; Erlichman C; Kaufmann SH
Clin Cancer Res; 2001 May; 7(5):1438-45. PubMed ID: 11350915
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
Glass TL; Liu TJ; Yung WK
Neuro Oncol; 2000 Jul; 2(3):151-8. PubMed ID: 11302335
[TBL] [Abstract][Full Text] [Related]
13. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
Della Corte CM; Ciaramella V; Di Mauro C; Castellone MD; Papaccio F; Fasano M; Sasso FC; Martinelli E; Troiani T; De Vita F; Orditura M; Bianco R; Ciardiello F; Morgillo F
Oncotarget; 2016 Jan; 7(4):4265-78. PubMed ID: 26673006
[TBL] [Abstract][Full Text] [Related]
14. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
Oh SH; Kim WY; Kim JH; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK; Lee HY
Clin Cancer Res; 2006 Jan; 12(2):653-61. PubMed ID: 16428512
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.
Oh SH; Whang YM; Min HY; Han SH; Kang JH; Song KH; Glisson BS; Kim YH; Lee HY
Int J Cancer; 2012 Nov; 131(10):2253-63. PubMed ID: 22362554
[TBL] [Abstract][Full Text] [Related]
16. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.
Cho Y; Park MJ; Park M; Min SS; Yee J; Kim C; Han MS; Han SH
Respirology; 2009 Aug; 14(6):850-8. PubMed ID: 19703066
[TBL] [Abstract][Full Text] [Related]
17. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
Feldkamp MM; Lau N; Roncari L; Guha A
Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
[TBL] [Abstract][Full Text] [Related]
18. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
20. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
